Shares in Alcon fell as much as 11.6% on Wednesday after the Swiss-American eye care group cut its 2025 sales outlook late on ...

The company said it expects a $100 million hit from tariffs this year.

Swiss-American eye care firm Alcon Inc (NYSE:ALC) stock slumped on Wednesday after the company cut its 2025 outlook late on ...

Alcon remains a leader in eye care, benefiting from strong market positioning and long-term industry tailwinds. Read the ...

Alcon (NYSE:ALC) is down ~9% in Wednesday trading after releasing Q2 financial results after Tuesday's closing bell that ...

Traders braced for earnings from big-name retailers Lowe’s and Target. Palantir and Intel stocks fell as the tech selloff ...

ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.

Alcon (NYSE:ALC) stock continues to decline as J.P. Morgan downgrades the company following mixed Q2 2025 results and lowered sales guidance. Read more here.

Alcon affirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus consensus of $3.12. The company lowered 2025 sales guidance from $10.4 billion-$10.5 billion to $10.3 billion-$10.4 billion, ...

The company forecasts a full-year gross tariff impact of around $100 million, up from $80 million expected previously ...

Alcon Inc (ALC) reports steady revenue growth and strategic acquisitions, despite facing market pressures and competitive challenges.

Global eye care leader Alcon has announced it will acquire Lake Forest-based Staar Surgical, a manufacturer of implantable ...